MX2018003832A - Inhibidor de piridina alquinil prolil hidroxilasa, y metodo de preparacion y uso medico del mismo. - Google Patents
Inhibidor de piridina alquinil prolil hidroxilasa, y metodo de preparacion y uso medico del mismo.Info
- Publication number
- MX2018003832A MX2018003832A MX2018003832A MX2018003832A MX2018003832A MX 2018003832 A MX2018003832 A MX 2018003832A MX 2018003832 A MX2018003832 A MX 2018003832A MX 2018003832 A MX2018003832 A MX 2018003832A MX 2018003832 A MX2018003832 A MX 2018003832A
- Authority
- MX
- Mexico
- Prior art keywords
- prolyl hydroxylase
- present
- preparation
- medical use
- hydroxylase inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere al campo de la química farmacéutica. En particular, la presente invención se refiere a una clase de inhibidores de alquinil piridin prolil hidroxilasa (I). El experimento muestra que dicho compuesto tiene una buena actividad de inhibición de la prolil hidroxilasa y puede potenciar la generación y secreción de eritropoyetina en modelos celulares o animales, y por lo tanto puede promover la generación de glóbulos rojos, y puede usarse para el tratamiento o prevención de la anemia, como la anemia por enfermedad renal crónica y las enfermedades isquémicas, como los accidentes cerebrovasculares isquémicos, la isquemia miocárdica y otras enfermedades relacionadas. La presente invención también describe un método para preparar dicho compuesto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510648342.9A CN105130888A (zh) | 2015-10-09 | 2015-10-09 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
PCT/CN2015/095728 WO2017059623A1 (zh) | 2015-10-09 | 2015-11-27 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018003832A true MX2018003832A (es) | 2018-06-18 |
Family
ID=54716523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018003832A MX2018003832A (es) | 2015-10-09 | 2015-11-27 | Inhibidor de piridina alquinil prolil hidroxilasa, y metodo de preparacion y uso medico del mismo. |
Country Status (21)
Country | Link |
---|---|
US (2) | US10889546B2 (es) |
EP (1) | EP3360862B1 (es) |
JP (1) | JP6635562B2 (es) |
KR (1) | KR20180063229A (es) |
CN (2) | CN105130888A (es) |
AU (1) | AU2015411258B2 (es) |
BR (1) | BR112018005969A2 (es) |
CA (1) | CA3000040A1 (es) |
DK (1) | DK3360862T3 (es) |
ES (1) | ES2794002T3 (es) |
HK (1) | HK1247613A1 (es) |
HR (1) | HRP20200907T1 (es) |
HU (1) | HUE049409T2 (es) |
LT (1) | LT3360862T (es) |
MX (1) | MX2018003832A (es) |
PL (1) | PL3360862T3 (es) |
PT (1) | PT3360862T (es) |
RU (1) | RU2692494C1 (es) |
SI (1) | SI3360862T1 (es) |
UA (1) | UA120407C2 (es) |
WO (1) | WO2017059623A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105130888A (zh) | 2015-10-09 | 2015-12-09 | 中国药科大学 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
CN107417605A (zh) * | 2017-08-02 | 2017-12-01 | 江苏艾立康药业股份有限公司 | 作用于脯氨酰羟化酶的吡啶衍生化合物 |
EP3702350A4 (en) * | 2017-10-25 | 2021-03-17 | Jiangsu Hengrui Medicine Co., Ltd. | CRYSTALLINE FORM OF ALKINYLPYRIDINE PROLYL HYDROXYLASE INHIBITOR AND THE METHOD FOR MANUFACTURING IT |
CN110240562B (zh) * | 2018-03-08 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 一种脯氨酰羟化酶抑制剂的可药用盐、晶型及其制备方法 |
CN111094246B (zh) * | 2018-05-24 | 2023-03-10 | 苏州盛迪亚生物医药有限公司 | 一种用于制备炔基吡啶类脯氨酰羟化酶抑制剂的方法 |
CN109593084B (zh) * | 2019-01-23 | 2021-09-28 | 中国药科大学 | 脯氨酰羟化酶小分子光敏前药及其制备方法与应用 |
CA3131445A1 (en) * | 2019-03-04 | 2020-09-10 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition of prolyl hydroxylase inhibitor and preparation method therefor |
CN112741834A (zh) * | 2021-02-07 | 2021-05-04 | 复旦大学附属中山医院 | HIF-1α降解抑制剂在制备酮体水平升高的冠心病药物中的应用 |
CN116120340B (zh) * | 2021-11-15 | 2023-10-31 | 艾立康药业股份有限公司 | 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途 |
CN116514710A (zh) * | 2022-01-21 | 2023-08-01 | 中国药科大学 | 环取代炔基吡啶甲酰甘氨酸衍生物、制备方法、药物组合物和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4410480A1 (de) * | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
PL3357911T3 (pl) * | 2006-06-26 | 2022-09-05 | Akebia Therapeutics Inc. | Inhibitory prolilohydroksylazy i sposoby ich użycia |
CA2672652C (en) * | 2006-12-18 | 2012-04-17 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
TW200845991A (en) * | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
TW201141839A (en) * | 2010-04-19 | 2011-12-01 | Daiichi Sankyo Co Ltd | Substituted 5-hydroxypyrimidine-4-carboxamide compounds |
US9738604B2 (en) * | 2010-09-03 | 2017-08-22 | Duke University | Ethynylbenzene derivatives |
US9206134B2 (en) * | 2011-07-22 | 2015-12-08 | Beijing Betta Pharmaceuticals Co. Ltd. | Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
CN105130888A (zh) * | 2015-10-09 | 2015-12-09 | 中国药科大学 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
-
2015
- 2015-10-09 CN CN201510648342.9A patent/CN105130888A/zh active Pending
- 2015-11-27 KR KR1020187012413A patent/KR20180063229A/ko not_active Application Discontinuation
- 2015-11-27 HU HUE15905721A patent/HUE049409T2/hu unknown
- 2015-11-27 CA CA3000040A patent/CA3000040A1/en not_active Abandoned
- 2015-11-27 JP JP2018515119A patent/JP6635562B2/ja not_active Expired - Fee Related
- 2015-11-27 MX MX2018003832A patent/MX2018003832A/es unknown
- 2015-11-27 RU RU2018113258A patent/RU2692494C1/ru active
- 2015-11-27 BR BR112018005969-2A patent/BR112018005969A2/pt not_active Application Discontinuation
- 2015-11-27 AU AU2015411258A patent/AU2015411258B2/en not_active Ceased
- 2015-11-27 EP EP15905721.5A patent/EP3360862B1/en active Active
- 2015-11-27 LT LTEP15905721.5T patent/LT3360862T/lt unknown
- 2015-11-27 ES ES15905721T patent/ES2794002T3/es active Active
- 2015-11-27 DK DK15905721.5T patent/DK3360862T3/da active
- 2015-11-27 CN CN201580079971.2A patent/CN107848976B/zh active Active
- 2015-11-27 US US15/765,387 patent/US10889546B2/en active Active
- 2015-11-27 PL PL15905721T patent/PL3360862T3/pl unknown
- 2015-11-27 SI SI201531228T patent/SI3360862T1/sl unknown
- 2015-11-27 WO PCT/CN2015/095728 patent/WO2017059623A1/zh active Application Filing
- 2015-11-27 PT PT159057215T patent/PT3360862T/pt unknown
- 2015-11-27 UA UAA201804628A patent/UA120407C2/uk unknown
-
2018
- 2018-05-29 HK HK18107005.8A patent/HK1247613A1/zh unknown
-
2020
- 2020-06-07 HR HRP20200907TT patent/HRP20200907T1/hr unknown
- 2020-09-11 US US17/018,221 patent/US20200407319A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA3000040A1 (en) | 2017-04-13 |
CN107848976A (zh) | 2018-03-27 |
AU2015411258A1 (en) | 2018-05-10 |
JP2018529690A (ja) | 2018-10-11 |
SI3360862T1 (sl) | 2020-08-31 |
ES2794002T3 (es) | 2020-11-17 |
PT3360862T (pt) | 2020-05-27 |
BR112018005969A2 (pt) | 2018-10-16 |
US20200407319A1 (en) | 2020-12-31 |
EP3360862A4 (en) | 2018-08-15 |
WO2017059623A1 (zh) | 2017-04-13 |
LT3360862T (lt) | 2020-07-10 |
KR20180063229A (ko) | 2018-06-11 |
RU2692494C1 (ru) | 2019-06-25 |
HK1247613A1 (zh) | 2018-09-28 |
US20180305317A1 (en) | 2018-10-25 |
CN105130888A (zh) | 2015-12-09 |
AU2015411258B2 (en) | 2020-09-17 |
UA120407C2 (uk) | 2019-11-25 |
DK3360862T3 (da) | 2020-06-02 |
EP3360862B1 (en) | 2020-04-22 |
CN107848976B (zh) | 2020-11-17 |
US10889546B2 (en) | 2021-01-12 |
EP3360862A1 (en) | 2018-08-15 |
PL3360862T3 (pl) | 2020-09-21 |
JP6635562B2 (ja) | 2020-01-29 |
HUE049409T2 (hu) | 2020-10-28 |
HRP20200907T1 (hr) | 2020-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018003832A (es) | Inhibidor de piridina alquinil prolil hidroxilasa, y metodo de preparacion y uso medico del mismo. | |
PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
MX2018013983A (es) | Inhibidores g12c de kras. | |
MD20170016A2 (ro) | Compuşi aminopirimidinici ca inhibitori JAK | |
WO2015095819A3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
WO2017075629A3 (en) | Wee 1 kinase inhibitors and methods of making and using the same | |
MD4650B1 (ro) | Derivaţi de chinazolină utilizaţi în tratamentul HIV | |
NZ728162A (en) | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | |
PH12016501790B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
WO2016105525A3 (en) | Novel pyrimidines as egfr inhibitors and methods of treating disorders | |
MX2016002589A (es) | Composicion farmaceutica que contiene compuesto de pirimidina como ingrediente activo. | |
PH12016501788B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
PH12016501462A1 (en) | Neprilysin inhibitors | |
MX2019001011A (es) | Compuestos farmaceuticos. | |
EA201691244A1 (ru) | Фармацевтическая композиция, содержащая соединение пиридиламиноуксусной кислоты | |
MX2022006304A (es) | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. | |
TW201613932A (en) | Organic compounds | |
WO2015171558A3 (en) | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE | |
PH12018501237A1 (en) | Isoindole compounds | |
WO2016100738A3 (en) | Antifibrotic activity of gas6 inhibitor | |
IN2014MU01042A (es) | ||
PH12017501397A1 (en) | (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor | |
EA201692518A2 (ru) | Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила | |
PH12017501735A1 (en) | Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same | |
EA201692045A1 (ru) | Производное фенантролинфосфоновой кислоты и способ его получения и применения |